Noblesville council approves economic development agreement with Curium


During its Oct. 27 meeting, the Noblesville Common Council unanimously approved an economic development agreement with Curium US PET, a nuclear medicine company.

“For many reasons, we are fortunate in Noblesville to have economic development interests in our community,” Economic Development Director Andrew Murray said. “Year to date, we’ve had exciting project announcements, partnership announcements, and we have another exciting opportunity to acknowledge a new corporate use and corporate citizen who is locating in Noblesville through a recent business acquisition.”

With the approval, Curium will continue to grow its operation in Noblesville. It occupies the building at 14395 Bergen Blvd., which was previously occupied by Zevacor.

The economic development agreement approved by the council continues the remaining personal property abatement that was granted to Zevacor. The agreement is a seven-year property tax deduction at 95 percent. Curium pledged to staff no less than 30 employees by the end of 2022, retaining the 27 employees from the previous occupant and hiring at least three more. The jobs include management, research and development, engineering and more with an average salary of $85,000.

Curium Vice President and General Counsel Bob Budenholzer presented to the council, telling members that Curium has approximately 200 employees globally, and its products help 14 million patients each year. The products are mostly used in diagnostic imaging, but Budenholzer said the company wants to move toward therapeutic products.

“Nuclear medicine products are injected into a patient before an imaging procedure and help the doctor when they take the picture to get a lot better of a picture and the functioning of organs,” Budenholzer said. “There are different products designed to go to the kidney or heart or various organs.”

For more, visit or


Current Morning Briefing Logo

Stay CURRENT with our daily newsletter (M-F) and breaking news alerts delivered to your inbox for free!

Select list(s) to subscribe to

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact